Higher revenue and narrower loss in the biomedical business
First written in FY2017-Q2. 17 of 31 entries say "Worsened", first in FY2018-Q1. Latest entry: FY2026.
Pharma Foods International moved to the "Worse" side of this theme in 2022.
0 other companies' latest entry also says "Worsened".
- FY2026WorsenedAnnual report
「As a result, biomedical business sales for the current consolidated fiscal year were ¥350 million, up 5.9% from the previous fiscal year, while the segment loss was ¥838 million, compared with a loss of ¥378 million in the previous fiscal year.」
Although the biomedical business reported higher sales, its segment loss widened from ¥378 million to ¥838 million. - FY2025-H1AdvancedAnnual report
「As a result, revenue from the Biomedical Business for the interim period was ¥135 million, up 15.6% year on year, and the segment loss was ¥199 million, compared with a segment loss of ¥224 million in the same period of the previous year.」
Revenue from the Biomedical Business increased 15.6% year on year, while the segment loss narrowed from ¥224 million to ¥199 million. - FY2024AdvancedAnnual report
「As a result, revenue from the Biomedical Business for the fiscal year was ¥478 million, up 39.4% year on year, and the segment loss was ¥272 million, compared with a segment loss of ¥278 million in the previous fiscal year.」
Revenue from the Biomedical Business increased 39.4% year on year to ¥478 million, while the segment loss narrowed from ¥278 million to ¥272 million. - FY2024-Q3WorsenedAnnual report
「As a result, revenue from the Biomedical Business for the cumulative third quarter was ¥231 million, down 18.3% year on year, and the segment loss was ¥315 million, compared with a loss of ¥177 million in the same period of the previous year.」
The Biomedical Business recorded lower revenue, and the segment loss widened from ¥177 million in the same period of the previous year to ¥315 million. - FY2024-Q2WorsenedAnnual report
「As a result, revenue from the Biomedical Business for the cumulative second quarter was ¥117 million, down 15.2% year on year, and the segment loss was ¥224 million, compared with a segment loss of ¥145 million in the same period of the previous year.」
The Biomedical Business recorded lower revenue, and the segment loss widened from ¥145 million in the same period of the previous year to ¥224 million. - FY2024-Q1WorsenedAnnual report
「As a result, revenue from the Biomedical Business for the cumulative first quarter was ¥57 million, down 4.4% year on year, and the segment loss was ¥121 million, compared with a segment loss of ¥69 million in the same period of the previous year.」
The Biomedical Business recorded lower revenue, and the segment loss widened from ¥69 million in the same period of the previous year to ¥121 million. - FY2023Higher sales alongside widening lossesAnnual report
「As a result, revenue from the Biomedical Business for the fiscal year was ¥343 million, up 55.8% year on year, while the segment loss was ¥278 million, compared with a segment loss of ¥231 million in the previous fiscal year.」
Revenue from the Biomedical Business increased 55.8% year on year to ¥343 million, while the segment loss widened from ¥231 million to ¥278 million. - FY2023-Q2Substantial revenue growth and continued lossesAnnual report
「As a result, revenue from the Biomedical Business for the cumulative second quarter was ¥138 million, up 880.0% year on year, while the segment loss was ¥145 million, compared with a loss of ¥138 million in the same period of the previous year.」
Revenue from the Biomedical Business increased 880.0% year on year, while the segment loss widened to ¥145 million. - FY2022WorsenedAnnual report
「As a result, revenue from the Biomedical Business for the fiscal year was ¥220 million, down 41.3% year on year, and the segment loss was ¥231 million, compared with segment profit of ¥81 million in the previous fiscal year.」
The Biomedical Business recorded lower revenue and turned profit in the previous fiscal year into a segment loss of ¥231 million. - FY2022-Q3WorsenedAnnual report
「As a result, revenue from the Biomedical Business for the cumulative third quarter was ¥47 million, compared with ¥350 million in the same period of the previous year, down 86.6% year on year, and the segment loss was ¥194 million, compared with segment profit of ¥128 million in the same period of the previous year.」
The Biomedical Business recorded a substantial decline in revenue and turned segment profit in the same period of the previous year into a loss of ¥194 million. - FY2022-Q2WorsenedAnnual report
「As a result, revenue from the Biomedical Business for the cumulative second quarter was ¥14 million, compared with ¥332 million in the same period of the previous year, down 95.7% year on year, and the segment loss was ¥138 million, compared with segment profit of ¥174 million in the same period of the previous year.」
Revenue from the Biomedical Business fell 95.7% year on year, and the business turned segment profit of ¥174 million in the same period of the previous year into a loss of ¥138 million. - FY2021AdvancedAnnual report
「As a result, revenue from the Biomedical Business for the fiscal year was ¥375 million, up 101.4% year on year, and segment profit was ¥81 million, compared with a loss of ¥45 million in the previous fiscal year.」
Due in part to upfront payments under the license agreement with Mitsubishi Tanabe Pharma, revenue from the Biomedical Business was ¥375 million and segment profit was ¥81 million, turning from a loss in the previous fiscal year to a profit. - FY2021-Q3AdvancedAnnual report
「As a result, revenue from the Biomedical Business for the cumulative third quarter was ¥350 million, up 108.3% year on year, and segment profit was ¥128 million, compared with a segment loss of ¥14 million in the same period of the previous year.」
Revenue from the Biomedical Business was ¥350 million, up 108.3% year on year, and the business turned a loss of ¥14 million in the same period of the previous year into profit of ¥128 million. - FY2021-Q2AdvancedAnnual report
「As a result, revenue from the Biomedical Business for the cumulative second quarter was ¥332 million, up 187.5% year on year, and segment profit was ¥174 million, compared with a segment loss of ¥8 million in the same period of the previous year.」
Revenue from the Biomedical Business was ¥332 million, up 187.5% year on year, and the business turned a loss of ¥8 million in the same period of the previous year into segment profit of ¥174 million. - FY2021-Q1WorsenedAnnual report
「As a result, revenue from the Biomedical Business for the cumulative first quarter was ¥4 million, compared with ¥106 million in the same period of the previous year, down 96.0% year on year, and the segment loss was ¥44 million, compared with segment profit of ¥66 million in the same period of the previous year.」
The company refrained from accepting contract testing orders in order to focus on research and development of new drug discovery targets. As a result, revenue fell 96.0% year on year, and the business turned from profit to loss. - FY2020-Q3WorsenedAnnual report
「As a result, revenue from the Biomedical Business for the cumulative third quarter was ¥168 million, down 1.2% year on year, and the segment loss was ¥14 million, compared with segment profit of ¥3 million in the same period of the previous year.」
The Biomedical Business recorded lower revenue and turned segment profit of ¥3 million in the same period of the previous year into a loss of ¥14 million. - FY2020-Q2WorsenedAnnual report
「As a result, revenue from the Biomedical Business for the cumulative second quarter was ¥115 million, compared with revenue of ¥156 million in the same period of the previous year, and the segment loss was ¥8 million, compared with segment profit of ¥24 million in the same period of the previous year.」
The Biomedical Business recorded lower revenue and turned a segment profit in the same period of the previous year into a loss of ¥8 million. - FY2020-Q1Lower revenue, higher earningsAnnual report
「As a result, revenue from the Biomedical Business for the cumulative first quarter was ¥106 million, compared with ¥139 million in the same period of the previous year, down 23.8% year on year, and segment profit was ¥66 million, compared with ¥44 million, up 49.0%.」
The Biomedical Business recorded lower revenue but higher segment profit than in the same period of the previous year, resulting in lower revenue and higher profit. - FY2019AdvancedAnnual report
「As a result, revenue from the Biomedical Business for the fiscal year was ¥231 million, up 531.6% year on year, and segment profit was ¥21 million, compared with a segment loss of ¥86 million in the previous fiscal year.」
Revenue from the Biomedical Business increased significantly, and the business turned a segment loss of ¥86 million in the previous fiscal year into a profit of ¥21 million. - FY2019-Q3AdvancedAnnual report
「As a result, for the cumulative third quarter of the current fiscal year, revenue from the Biomedical Business was ¥170 million, up 567.9% year on year, and segment profit was ¥3 million, compared with a segment loss of ¥61 million in the year-earlier period.」
Revenue in the Biomedical Business increased to ¥170 million, and the business turned from a loss of ¥61 million in the year-earlier period to segment profit of ¥3 million. - FY2019-Q2AdvancedAnnual report
「As a result, for the cumulative second quarter of the current fiscal year, revenue from the Biomedical Business was ¥156 million, compared with revenue of ¥11 million in the year-earlier period, and segment profit was ¥24 million, compared with a segment loss of ¥29 million in the year-earlier period.」
Revenue in the Biomedical Business increased to ¥156 million, and the business turned from a loss in the year-earlier period to segment profit of ¥24 million. - FY2019-Q1AdvancedAnnual report
「As a result, for the cumulative first quarter of the current fiscal year, revenue from the Biomedical Business was ¥139 million, up 5,889.1% year on year, and segment profit was ¥44 million, compared with a loss of ¥20 million in the previous fiscal year.」
Against the backdrop of upfront contract payments under joint research agreements with Mitsubishi Tanabe Pharma and others, the Biomedical Business turned from a segment loss in the previous fiscal year to segment profit of ¥44 million, while revenue also increased substantially. - FY2018-Q3WorsenedAnnual report
「As a result, for the cumulative third quarter of the current fiscal year, consolidated revenue was ¥25 million, down 36.8% year on year, and segment loss was ¥57 million, compared with a loss of ¥49 million in the year-earlier period.」
Revenue in the Biomedical Business declined 36.8% year on year, while segment loss widened from ¥49 million in the year-earlier period to ¥57 million. - FY2018-Q2WorsenedAnnual report
「As a result, for the cumulative second quarter of the current fiscal year, consolidated revenue was ¥11 million, down 56.9% year on year, and segment loss was ¥30 million, compared with a loss of ¥44 million in the year-earlier period.」
Segment loss narrowed from ¥44 million in the year-earlier period to ¥30 million, while revenue declined 56.9% year on year, and the trend of higher revenue did not continue. - FY2018-Q1WorsenedAnnual report
「For the cumulative first quarter of the current fiscal year, revenue was ¥2 million, down 72.3% year on year, due to income from contract antibody production services, the LSI Business and other factors. Segment loss was ¥20 million, compared with a loss of ¥33 million in the year-earlier period, due mainly to the recording of research and development expenses.」
Segment loss narrowed from ¥33 million in the year-earlier period to ¥20 million, while revenue fell 72.3% year on year to ¥2 million, representing a substantial deterioration from the trend of higher revenue. - FY2017-Q3RestatedAnnual report
「For the cumulative third quarter of the current fiscal year, revenue was ¥40 million, up 31.9% year on year, due to contract antibody production services, income from the LSI Business and other factors. Segment loss was ¥49 million, compared with a loss of ¥97 million in the year-earlier period, due mainly to the recording of research and development expenses.」
The company continued to disclose that the Biomedical Business posted higher revenue and that its segment loss narrowed year on year. - FY2017-Q2First statedAnnual report
「For the cumulative second quarter of the current fiscal year, revenue was ¥26 million, up 175.5% year on year, due to contract antibody production services, income from the LSI Business and other factors. Segment loss was ¥44 million, compared with a loss of ¥74 million in the year-earlier period, due mainly to the recording of research and development expenses.」
The company disclosed that the Biomedical Business posted higher revenue due to income from contract antibody production and the LSI Business, among other factors, while its segment loss narrowed from the year-earlier period.